{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:59:19Z","timestamp":1755795559547,"version":"3.41.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1141","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We investigated the influence of handling death and reirradiation on the estimation of duration of response (DOR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>First, we performed a scoping review on methods to assess DOR in palliative radiotherapy. Second, we performed three different analyses on a subgroup of patients from a previously published prospective study. The first analysis was a competing risks analysis considering relapse of pain as the event of interest and death and reirradiation as competing events (Analysis A). The second and third analyses were standard survival analyses where the event of interest was a composite outcome of relapse of pain, death, or reirradiation (Analysis B) and relapse of pain (Analysis C), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Death was considered as an event of interest in less than half of the papers, while reirradiation was not considered in any of the studies. Competing risks analysis was not performed in any of the studies. In the analysis of clinical data, competing risks analysis showed that relapse of pain predominated as the cause of the end of response. Median DOR was correctly estimated to be 4.1 months in Analyses A and B, but was overestimated to be 8.1 months in Analysis C.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Death and reirradiation should be treated as the events of interest that mark the end of response (as in Analyses A and B) to avoid overestimation of treatment efficacy and an invalid assumption of independent censoring.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>The definition of end of response remains inconclusive in the assessment of DOR. We recommend competing risks analysis (Analysis A), by which we can estimate cumulative incidence of each event type and evaluate the necessity of reirradiation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20220398","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:27:55Z","timestamp":1663676875000},"source":"Crossref","is-referenced-by-count":2,"title":["Bias due to statistical handling of death and reirradiation in the assessment of duration of response after palliative radiotherapy: a scoping review and analysis of clinical data"],"prefix":"10.1093","volume":"96","author":[{"given":"Tetsuo","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Arao Municipal Hospital , Arao, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Graduate School of Medicine, Kurume University , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, St. Marianna University School of Medicine , Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuo","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kumamoto University Hospital , Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2024050216064902000_b1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.2014.55.1143","article-title":"Role of radiation therapy in palliative care of the patient with cancer","volume":"32","author":"Lutz","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024050216064902000_b2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.21037\/apm.2018.10.02","article-title":"Defining the radiation oncologist\u2019s role in palliative care and radiotherapy","volume":"8","author":"Lam","year":"2019","journal-title":"Ann Palliat Med"},{"key":"2024050216064902000_b3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","article-title":"Update of the systematic review of palliative radiation therapy fractionation for bone metastases","volume":"126","author":"Rich","year":"2018","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b4","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2024050216064902000_b5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.adro.2019.06.003","article-title":"Single- versus multiple-fraction radiation therapy for painful bone metastases: a systematic review and meta-analysis of nonrandomized studies","volume":"4","author":"Saito","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"2024050216064902000_b6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00432-017-2519-y","article-title":"A revision of the tokuhashi revised score improves the prognostic ability in patients with metastatic spinal cord compression","volume":"144","author":"Morgen","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024050216064902000_b7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2014.10.055","article-title":"Cost-Effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases","volume":"91","author":"Kim","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/jnci\/djz101","article-title":"Systematic review of the role of stereotactic radiotherapy for bone metastases","volume":"111","author":"Spencer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2024050216064902000_b9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2024050216064902000_b10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0360-3016(94)90416-2","article-title":"Analysis of the probability and risk of cause-specific failure","volume":"29","author":"Caplan","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","article-title":"Cumulative incidence in competing risks data and competing risks regression analysis","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2024050216064902000_b12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2018.04.072","article-title":"Predictors of pain palliation after radiation therapy for painful tumors: a prospective observational study","volume":"101","author":"Saito","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","article-title":"Update of the International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases","volume":"82","author":"Chow","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i07","article-title":"Mstate: an R package for the analysis of competing risks and multi-state models","volume":"38","author":"de Wreede","year":"2011","journal-title":"J Stat Softw"},{"key":"2024050216064902000_b15","first-page":"43","article-title":"Palliative radiotherapy in bone metastases: results of a randomized trial comparing three fractionation schedules","volume":"6","author":"Ozsaran","year":"2001","journal-title":"J BUON"},{"key":"2024050216064902000_b16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0360-3016(01)01495-X","article-title":"Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International atomic energy agency (IAEA)","volume":"50","author":"Salazar","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European organisation for research and treatment of cancer, genitourinary group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"2024050216064902000_b18","first-page":"261","article-title":"20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases. A multicenter randomized study","volume":"53","author":"Badzio","year":"2003","journal-title":"J Oncol"},{"key":"2024050216064902000_b19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.radonc.2004.09.017","article-title":"Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05)","volume":"75","author":"Roos","year":"2005","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2005.08.193","article-title":"Short-Course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial","volume":"23","author":"Maranzano","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024050216064902000_b21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2006.02.007","article-title":"Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch bone metastasis study","volume":"78","author":"van der Linden","year":"2006","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.radonc.2006.05.006","article-title":"Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy X 1) versus multiple fractions (3 Gy X 10) in the treatment of painful bone metastases","volume":"79","author":"Kaasa","year":"2006","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b23","first-page":"439","article-title":"The effect of a single fraction compared to multiple fractions radiotherapy on painful bone metastases with evaluation of computed tomography bone density in osteolytic bone metastases","volume":"42","author":"El-Shenshawy","year":"2006","journal-title":"Bull Alex Fac Med"},{"key":"2024050216064902000_b24","first-page":"35","article-title":"Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases","volume":"1","author":"Hamouda","year":"2007","journal-title":"Gulf J Oncolog"},{"key":"2024050216064902000_b25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2008.05.018","article-title":"Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction","volume":"89","author":"Foro Arnalot","year":"2008","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.radonc.2009.05.012","article-title":"8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial","volume":"93","author":"Maranzano","year":"2009","journal-title":"Radiother Oncol"},{"key":"2024050216064902000_b27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00520-009-0663-x","article-title":"Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study","volume":"18","author":"Atahan","year":"2010","journal-title":"Support Care Cancer"},{"key":"2024050216064902000_b28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.rpor.2014.04.009","article-title":"Radiation therapy for the management of painful bone metastases: results from a randomized trial","volume":"19","author":"Guti\u00e9rrez Bayard","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"2024050216064902000_b29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2017.09.030","article-title":"Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bony metastases: a phase 3 prospective, randomized, controlled trial","volume":"100","author":"Chi","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050216064902000_b30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.14740\/wjon1118w","article-title":"Comparison of single versus multifraction radiotherapy in palliation of painful bone metastases","volume":"9","author":"Nongkynrih","year":"2018","journal-title":"World J Oncol"},{"key":"2024050216064902000_b31","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.7150\/jca.28674","article-title":"A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma","volume":"10","author":"He","year":"2019","journal-title":"J Cancer"},{"key":"2024050216064902000_b32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2024050216064902000_b33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-11-2097","article-title":"The use and interpretation of competing risks regression models","volume":"18","author":"Dignam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024050216064902000_b34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis","volume":"122","author":"Schuster","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2024050216064902000_b35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10543406.2016.1107709","article-title":"Data analysis with competing risks and intermediate states, edited by Ronald B. geskus","volume":"26","author":"Wilkes","year":"2016","journal-title":"J Biopharm Stat"},{"key":"2024050216064902000_b36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jclinepi.2016.11.017","article-title":"The number of primary events per variable affects estimation of the subdistribution hazard competing risks model","volume":"83","author":"Austin","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2024050216064902000_b37","first-page":"217","article-title":"Poor accrual in palliative research studies: an update from the rapid response radiotherapy program","volume":"2","author":"Lien","year":"2011","journal-title":"World J Oncol"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1141\/20220398\/57370747\/bjr.20220398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1141\/20220398\/57370747\/bjr.20220398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:28:52Z","timestamp":1714674532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20220398\/7458139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":37,"journal-issue":{"issue":"1141","published-online":{"date-parts":[[2022,10,10]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20220398","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"type":"print","value":"0007-1285"},{"type":"electronic","value":"1748-880X"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,10,10]]},"article-number":"20220398"}}